Did you finish first line chemo for stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer between 20 Sept 2021 and 20 July 2022?

[OvacomeSupport]

Good afternoon everyone,

Did you finish first line chemo for stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer between 20 Sept 2021 and 20 July 2022?

If so, you may be eligible to take part in an important new study which aims to identify areas for improvement in supporting the lives of patients at different stages of their treatment pathway and to contribute to the mutual understanding between patients and their consultants, nurses and surgeons.

As well as looking at the emotional and physical effects felt by patients after treatment, it will investigate whether clinicians understand these challenges and how they might be supported to address the clinical and emotional needs of those they treat.

This study involves completing a survey. This is non-interventional observational study, meaning that participants will not receive any treatment as part of the study.

All study participants will receive £50 on successful completion of the survey.

Here is some further information about criteria for participation:

• You must have received treatment in the UK.

• You must be over 18.

• You must have been diagnosed with epithelial ovarian cancer (high grade serous, low grade serous, endometrioid, clear cell, mucinous), fallopian tube cancer, or primary peritoneal cancer.

• You must have been diagnosed at stage 3 or 4.

• As first line treatment you must have had either:

Chemotherapy only

Surgery and then chemotherapy

Chemotherapy, followed by surgery, followed by more chemotherapy

• You must have finished your first line chemotherapy treatment between two and 12 months prior to taking part in the survey.

If you would like to know more about this study, please visit ovacome.org.uk/news/patron.

If you would like to participate in this study please contact Serena Lavin at the fieldwork agency via 01625 668988 or [e-mail]

To learn more, you can also contact the Ovacome support team on 0800 008 7054 or by emailing [e-mail]. Please don’t hesitate to get in touch if we can help with any further information or if there is anything we can do to support your participation.

If you have already completed the study or aren't eligible to participate, it would be much appreciated if you could share details of the study with your clinical teams or any contacts who may be eligible to take part.

Best wishes

Cathryn

Ovacome Support